David W. Brankow is a notable inventor based in Northridge, California. He has made significant contributions to the field of biotechnology, particularly in the development of proteins that target human receptors. With a total of five patents to his name, Brankow's work has the potential to impact the treatment of various medical conditions.

Latest Patents

Brankow's latest patents focus on human CGRP receptor binding proteins. These antigen binding proteins are designed to bind to the human CGRP receptor (CGRP R). The patents also include nucleic acids encoding the antigen binding protein, as well as vectors and cells that encode the same. The primary function of these antigen binding proteins is to inhibit the binding of CGRP R to CGRP. This innovation is particularly useful in addressing CGRP R related disorders, including the treatment and prevention of migraine headaches.

Career Highlights

David W. Brankow is currently associated with Amgen Inc., a leading biotechnology company. His work at Amgen has allowed him to further his research and development efforts in the field of receptor binding proteins. Brankow's contributions have been instrumental in advancing the understanding of CGRP R and its implications for migraine treatment.

Collaborations

Throughout his career, Brankow has collaborated with esteemed colleagues such as Shaw-Fen Sylvia Hu and Thomas Charles Boone. These collaborations have enriched his research and have led to significant advancements in the field.

Conclusion

David W. Brankow's innovative work in the development of human CGRP receptor binding proteins showcases his dedication to advancing medical science. His contributions have the potential to improve the lives of many individuals suffering from migraine headaches and related disorders.

This text is generated by artificial intelligence and may not be accurate.